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Introduction: Neuropathic pain associated with Non-freezing Cold Injury (NFCI) is a
major burden to military service personnel. A key feature of NFCI is reduction of the
intra-epidermal nerve fibre density in skin biopsies, in keeping with painful neuropathy.
Current oral treatments are generally ineffective and have undesirable side effects.
Capsaicin 8% patch (Qutenza) has been shown to be well-tolerated and effective for
reducing neuropathic pain, for up to 3 months after a single 30-minute application.
Methods: In this single-centre open label study, 16 military participants with NFCI (mean
duration 49 months) received 30-minute Capsaicin 8% patch treatment to the feet and
distal calf. Pain symptoms were assessed using a pain diary (with the 11-point Numerical
Pain Rating Scale, NPRS) and questionnaires, the investigations included skin biopsies,
performed before and three months after treatment.
Results: Participants showed significant decrease in spontaneous pain (mean NPRS:
−1.1, 95% CI: 0.37 to 1.90; p = 0.006), and cold-evoked pain (−1.2, 95% CI: 0.40 to
2.04; p= 0.006). The time-course of pain relief over 3 months was similar to other painful
neuropathies. Patient Global Impression of Change showed improvement (p = 0.0001).
Skin punch biopsies performed 3 months after the patch application showed significant
increase of nerve fibres with structural marker PGP9.5 (intra-epidermal nerve fibres
[IENFs], p < 0.0001; sub-epidermal nerve fibres [SENFs]; p =< 0.0001), and of
regenerating nerve fibres with their selective marker GAP43 (p = 0.0001). The increase
of IENFs correlated with reduction of spontaneous (p = 0.027) and cold-evoked pain
(p = 0.019).
Conclusions: Capsaicin 8% patch provides an exciting new prospect for treatment of
NFCI, with regeneration and restoration of nerve fibres, for the first time, in addition to
pain relief.
Keywords: capsaicin 8% patch, non-freezing cold injury, neuropathic pain, clinical trial, skin biopsy
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INTRODUCTION
Cold temperatures may lead to different clinical injuries,
depending on the rapidity, severity, and duration of the cold
exposure. The condition now termed Non-freezing cold injury
(NFCI) was previously called Trench Foot, and it has been known
since World Wars I and II to be a vaso-neuropathy (1–3). NFCI
and the associated chronic neuropathic pain are a particular
burden to military personnel (3–9).
An underlying small fibre neuropathy and neuro-vascular
changes have been demonstrated recently in skin biopsies,
which may account for the chronic pain and persistent cold
hypersensitivity (3). Currently prescribed oral treatments for
neuropathic pain generally have limited efficacy, with multiple
side effects. Further, there are no treatments that can cure
or even modify the underlying condition. NFCI may lead to
a downgrading of functional status, and in many cases early
discharge from the armed services.
An effective treatment, licenced in the UK/EU for neuropathic
pain, is the Capsaicin 8% patch (“Qutenza 179mg cutaneous
patch”), which may relieve pain for up to 3 months after a
single 30-minute application (10–12). This treatment is localised
to skin, and not associated with significant systemic absorption
or generalised side effects. The active ingredient capsaicin
is the substance in chilli peppers that gives them their hot
pungency (10).
A key feature of NFCI with neuropathic pain is a reduction in
intra-epidermal nerve fibre density in the skin, with dysfunction
of the residual small sensory nerve fibres, as in many other causes
of painful neuropathy. Thus, neuropathic pain associated with
NFCI can be treated with the Capsaicin 8% patch, as licenced.
The Capsaicin 8% patch has been shown by us in another
chronic neuropathic condition (chemotherapy-induced painful
neuropathy) to both relieve pain long term, and ameliorate the
underlying pathological nerve damage, with regeneration and
restoration of sensory nerve fibres (13).
In this study, we have investigated the effect of Capsaicin
8% patch treatment in subjects with NFCI related painful
neuropathy, as licenced (i.e. 3-monthly, if required). Our aim
was to relate any pain relief to sensory assessments and skin
biopsy findings. These tests are used routinely for diagnosing
and monitoring patients with small fibre neuropathy caused by a
range of medical conditions. Our observations would potentially
advance the understanding and management of NFCI.
MATERIALS AND METHODS
Study Design
This was a single-centre longitudinal open label study on
the effects of Capsaicin 8% patch treatment as licenced,
to be conducted in 20 participants with NFCI related to
military duties. Study approval was obtained from the Ministry
of Defence Research Ethics Committee (Ethics reference
number: 890/MoDREC/18).
Participants
Twenty subjects consented to take part in the study. Data
are reported here for the 16 participants who completed the
TABLE 1 | Participant demographics and characteristics.
Parameters
Number of participants n = 16
Age, Years
Mean ± SD 36 ± 7.4
Range 25–56
Sex, n (%)
Female 0 (0%)
Male 16 (100%)
Duration of Non-freezing cold injury, Mean, Months (Range; SD)
49 (10–120; 33)
Ethnicity, n (%)
African/Caribbean 11 (69%)
Caucasian 4 (25%)
Other Ethnic origin 1 (6%)
Exposure history, n (%)
Cold wet environment 7 (44%)
Cold windy environment 2 (13%)
Cold dry environment 7 (44%)
Duration of exposure to cold environment before onset of symptoms, n (%)
< 1h 2 (13%)
< 24 h 5 (31%)
< 1 week 2 (13%)
1 week 3 (19%)
>1 week 4 (25%)
Description of pain, n (%)
Cold evoked pain 16 (100%)
Burning pain 11 (69%)
Stabbing pain 1 (6%)
Other 4 (25%)
Baseline pain score (NPRS), Mean (Range; SD), n (%)
Spontaneous pain 6.0 (2.7–8.5; 1.9)
Cold evoked pain 6.8 (5.0 – 8.9; 1.2)
Medications for pain, n (%)
Pregabalin 1 (7%)
Duloxetine 1 (7%)
Amitriptyline 3 (20%)
Gabapentin 2 (13)
Other 2 (13)
NCS (mean ± SEM; Range)
Left sural sensory action potential amplitude 22.2 ± 1.7(13.0–33.0) mV
Left sural nerve conduction velocity 55.9 ± 4.7 (7.7–76.4) m/s
Right sural sensory action potential amplitude 21.1 ± 1.7 (15.0–35.0) mV
Right sural nerve conduction velocity 56.8 ± 2.6 (40.0–72.7) m/s
SD, Standard Deviation; n, Number of participants; SEM, Standard error of mean; NCS,
Nerve conduction studies.
follow-up visit at 3 months after single 30-minute application of
Capsaicin 8% patch. Four participants withdrew from the study
for personal reasons, unrelated to the study itself. Participants in
the study received Capsaicin 8% patch application to both feet up
to the distal calf. They continued to take their other medications
(but not topical treatments) before and during the study.
Participant demographics and characteristics (n = 16) are
recorded in Table 1.
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TABLE 2 | Results at baseline and at 3 month follow-up for participants with NFCI treated with Capsaicin 8% patch for spontaneous or cold-evoked pain (NPRS; paired
t-test), Patient Global Impression of Change (PGIC; paired t-test, baseline PGIC was change from screening to baseline visit), and the skin biopsies.
NUMERICAL PAIN RATING SCALE (NPRS) SCORE FOR SPONTANEOUS PAIN [MEAN ± SEM]
Spontaneous pain Baseline 3 Month FU p-value
6.0 ± 0.5 4.8 ± 0.6 **p = 0.006
Cold evoked pain Baseline 3 Month FU p-value
6.8 ± 0.3 5.6± 0.6 **p = 0.006
Baseline 3 Month FU p-value
Patient Global Impression of
Change (PGIC) [Mean ± SEM]
4 ± 0.09 3 ± 0.4 ***p = 0.0001
SKIN BIOPSY
Mean SD SEM p value; n = 16
PGP9.5 IENF Baseline 3.36 1.62 0.40 ***p < 0.0001
3 months FU 7.11 2.47 0.62
Mean SD SEM p value; n = 16
SENF Baseline 1.41 0.41 0.10 ***p < 0.0001
3 months FU 2.26 0.64 0.16
Mean SD SEM p value; n = 16
GAP43 SENFs Baseline 0.24 0.15 0.04 ***p = 0.0001
3 months FU 0.88 0.48 0.12
Mean SD SEM p value; n = 15
vWF Baseline 3.24 1.25 0.33 p = 0.80
3 months FU 3.35 1.29 0.32
SEM, Standard error of the mean; FU, follow up.
Participants were given a pain diary to complete, starting
on the day of screening and for the next 7 days. The
diary collected pain rating scores twice daily. An 11-point
Numerical Pain Rating Scale (NPRS), with the 0-anchor point
being “no pain”, and the 10-anchor point being “pain as
bad as you can imagine”, to describe “pain on average in
the last 24 hours”, was used for both spontaneous and
evoked pain.
After completing this diary for 7 days, the NPRS score was
used to determine eligibility for the study. Only subjects with
average pain intensity equal to or greater than 4/10 on the
NPRS scale were eligible to participate further in the study (they
were unaware of this criterion). They were advised to continue
completing the diary daily for the entire duration of the study,
until the end-of-study follow up visit.
Application of Capsaicin 8% patch was performed within 1
month from the baseline visit (in 5 subjects a baseline biopsy
was available from an earlier time-point, performed for diagnosis
with similar findings). 16 participants had follow-up assessments
3 months after Capsaicin 8% patch application.
The mean± SEM of the Numerical Pain Rating Score (NPRS)
at the first visit was 6.0 ± 0.5 and 6.8 ± 0.3 for spontaneous and
cold-induced pain respectively (Table 2).
Clinical Examination
Clinical examination and tests confirmed that participants
had a predominantly sensory neuropathy. Neurological deficits
were recorded using the Neuropathy Impairment Score Lower
Limbs (NIS-LL) (14), which is a summed score including of
muscle power, reflex loss (maximum score 88, indicating severe
neuropathy). The mean (SEM) NIS-LL at the baseline visit was
5.7 (1.2).
Assessment of Neuropathy
Clinical examination and tests were performed in both lower
and upper limbs. Nerve conduction studies were performed by
a senior consultant neurophysiologist.
Short-Form McGill Pain Questionnaire (SF-MPQ-2)
Symptoms were also recorded using the Short-FormMcGill Pain
Questionnaire (15), with maximum score 220, indicating severe
symptoms. The SF-MPQ-2 is composed of 4 summary scales: (1)
continuous, (2) intermittent, (3) neuropathic and (4) affective
pain descriptors.
Patient Global Impression of Change
Patients were asked to complete the Clinical Global Impression
of Change; this was completed at the baseline visit and
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three-monthly visits. The Questionnaire is composed of a 7-point
scale, enabling the patient to indicate no change, improvement or
worsening of their condition.
Quantitative Sensory Testing
For quantitative sensory testing (QST), thresholds for light touch
were measured using Semmes–Weinstein hairs (made by A.
Ainsworth, University College London, UK); No. 1 (0.0174 g) to
No. 20 (263.0 g). The hair with the lowest force reliably detected
by the patient on the dorsum of the toe was recorded. Values
>0.0479 g were considered abnormal (16).
Vibration perception thresholds were measured using a
biothesiometer (Biomedical Instrument Company, Newbury,
OH, USA) placed on the metatarsophalangeal joint of the big
toe. Three ascending and three descending trials were carried
out, and the mean value obtained. Values >12V were considered
abnormal (17).
Thermal perception thresholds were performed as described
(18, 19) using the TSA II–NeuroSensory Analyzer (Medoc,
Ramat Yishai, Israel). A 30 × 30mm thermode was used and
thermal thresholds determined in the soles of the feet (under
the instep), for warm perception, cool perception, heat pain
and cold pain from a baseline temperature of 32◦C, with a
change in temperature of 1◦C/s. The mean of three consecutive
tests for each modality was recorded. Mean variations from
baseline temperature >6.4◦C for warm sensation, >2.3◦C for
cool sensation and >10.4◦C for heat pain, were considered
abnormal (20).
Nerve Conduction Studies
Nerve conduction and sympathetic skin response (SSR) studies
were performed only at baseline to characterise the neuropathy,
on a Medtronic Keypoint electromyogram system (Medtronic,
Minneapolis, MN, USA) (3). Antidromic sensory action
potentials for the sural and superficial peroneal nerves and
orthodromic sensory action potentials for the medial and
lateral plantar, median, and ulnar nerves on both sides were
recorded. For the sural, superficial peroneal, medial plantar,
and ulnar nerves, action potentials of <5 µV amplitude were
considered abnormal, while for the lateral plantar and median
nerves, amplitudes of <2.5 and <10 µV were considered
abnormal, respectively. Sensory conduction velocities of<50 and
40 m/s were considered abnormal for upper and lower limb
nerves, respectively. The nerve compound action potentials were
recorded using standard described techniques, and the issue of
skin resistance was mitigated by: i) carrying out pre-recording
skin preparation identically in all subjects, and ii) by using
the identical type of recording electrodes in all subjects. These
were also the methods employed while collecting normative
data from our control subjects. SSRs were recorded from both
palms and both soles in response to a sudden unexpected tactile
stimulus and a sudden inspiratory gasp. An absent SSR was
considered abnormal.
Calf Skin Biopsy and Immunohistochemistry
3.5-mm diameter skin punch biopsies were collected under local
anaesthesia from the distal lateral calf at baseline (Visit 1) before
Capsaicin 8% patch application, and repeated 3 months after
treatment, within the area of Capsaicin 8% patch treatment. Skin
biopsies from age and gender-matched healthy volunteers were
analysed alongside as controls.
The immunohistochemical methods and antibodies used were
reported in detail previously (3, 19–22). The antibodies were
to the pan-neuronal structural nerve marker PGP 9.5 (Rabbit,
RA95/06, 1:40,000; Ultraclone, Isle of Wight, UK), the nerve
fibre regeneration marker, growth associated protein GAP-43
(G9264, Mouse, 7B10, 1:80,000; Sigma, Poole, UK), and marker
for blood vessels von Willebrand factor vWF (Rabbit, 1:10,000;
Novocastra Laboratories, Milton Keynes, UK). Briefly, the skin
biopsy was immersed in fixative (modified Zamboni’s fluid –
2% formalin; 0.01M phosphate buffer; 15% saturated picric
acid (pH 7.2), then washed in phosphate buffered saline (PBS;
0.1M phosphate; 0.9% w/v saline; pH 7.3) containing 15% w/v
sucrose for an hour, before snap freezing in optimum cutting
tissue embedding medium (Tissue-Tek OCT, RA Lamb Ltd,
Eastbourne, U.K.). Frozen sections were collected for processing
(50µm for PGP9.5, 30µm for GAP-43, and 15µm for vWF).
For GAP-43 and vWF, sections were collected onto poly-L-
lysine (Sigma, Poole, UK) coated glass slides; for PGP9.5, 50µm
sections were floated onto PBS in 12-well plates, and processed
further as described (3). Sites of primary antibody attachment
were revealed using nickel-enhanced, avidin-biotin peroxidase
(ABC - Vector Laboratories, Peterborough, UK). Sections
were counterstained for nuclei in 0.1% w/v aqueous neutral
red, air dried and mounted in xylene-based mountant (DPX;
BDH/Merck, Poole, UK).
Nerve fibres were counted along the length of four non-
consecutive sections. The length of epithelium in each counted
section was measured using computerised microscopy software
(Olympus ANALYSIS 5.0 Soft, Olympus UK, Southend, Essex,
UK) and results expressed as fibres/mm length of the section.
Sub-epidermal nerve immunoreactivity was obtained as a
percentage (% area), measured by image analysis where digital
photomicrographs were captured via video link to an Olympus
BX50 microscope. The grey-shade detection threshold was set at
a constant level to allow detection of positive immunostaining
and the area of highlighted immuno-reactivity was expressed as a
percentage (% area) of the field scanned. Images were captured
(×40 objective magnification) along the entire length, and the
mean values were used for statistical analysis. The GAP43 IENFs
were sparse and so only SENFs were analysed.
Skin biopsy analyses and quantification were performed
independently of the clinical data collection. Validation of these
methods for assessment of skin biopsies have been published
previously (22).
Statistical Analysis
Data were analysed using GraphPad Prism version 5.0 for
Windows (GraphPad Prism Software, San Diego, CA, USA). The
statistical tests used were paired two-tailed Mann-Whitney test,
Student’s t-test, two-way ANOVA analysis, Dunnett’s Multiple
Comparison Test, and Spearman’s correlation test. For all
statistical tests, p values < 0.05 were considered significant.
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FIGURE 1 | Time-course of pain relief in participants with NFCI treated with Capsaicin 8% patch. Time-course of pain scores for spontaneous pain (A, B) and cold
evoked pain (C, D). Repeated measures ANOVA for baseline to week 12 period was statistically significant for spontaneous pain (F = 2.4; **p = 0.005); and cold
evoked pain (F = 2.1; *p = 0.01); statistically significant difference was observed for the overall pain scores 3 months after the treatment (paired t test, B and D). 95%
CI shown for spontaneous pain weekly (A, C), and p values, with Dunnett’s Multiple Comparison Test (for a significance level of 0.05).
RESULTS
Material and Methods
Pain Scores and Questionnaires
There was a significant reduction in the NPRS scores three
months after Capsaicin 8% patch application (baseline week
vs. week 12) for both spontaneous (Table 2, Figures 1A,B) and
cold-evoked pain (Figures 1C,D). The mean difference of NPRS
score between baseline and 3-month follow-up visit was −1.1
(95% CI: 0.37 to 1.90; ∗∗p = 0.006) for spontaneous pain, and
−1.2 (95% CI 0.40 to 2.04; ∗∗p = 0.006) for cold-evoked pain.
Reduction from baseline was 20%, which would generally be
regarded as clinically significant.
At follow-up 3 months after the treatment, SF-MPQ-2 did not
show significant reduction in overall pain score (p = 0.23) or
pain scores recorded by using other descriptor category groups
(continuous pain, p = 0.11; intermittent pain, p = 0.32; affective
pain, p= 0.64; neuropathic pain, p= 0.30).
There was no significant difference in the NIS-LL
score 3 months after the treatment of capsaicin 8% patch
(p= 0.78).
The Capsaicin 8% patch application was well-tolerated, there
were no adverse events reported.
Nerve Conduction Studies
Four participants (25%) showed abnormalities, restricted to
the sensory action potential amplitude of plantar nerves. Sural
sensory action potential (mean ± SEM) was 22.2 ± 1.7 (13.0–
33.0) µV and 21.1 ± 1.7 (15.0 – 35.0) µV in left leg and right leg
respectively. The sural nerve velocity (mean ± SEM) was 55.9 ±
4.7 (7.7–76.4) m/s in left leg and 56.8 ± 2.6 (40.0–72.7) m/s in
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FIGURE 2 | Immunohistochemistry results in skin biopsies for PGP9.5-positive nerve fibres. (A) Intra-epidermal PGP9.5 nerve fibres (IENFs/mm) at baseline (Q PRE),
and significant increase at 3 months after treatment (Q POST) with Capsaicin 8% patch Qutenza (Q) (paired t-test). Statistically significant difference between control
group and baseline (Q PRE), but not significant after treatment (Q POST) (Mann-Whitney test). (B) Sub-epidermal PGP9.5 nerve fibres (SENFs; % Area) at baseline (Q
PRE) and 3 months after treatment (Q POST) with Capsaicin 8% patch Qutenza (Q). Statistically significant increase after Capsaicin 8% patch application (paired
t-test). Statistically significant difference between control and treated group before (Q PRE) but not after (Q POST) Capsaicin 8% patch application (Mann-Whitney test).
right leg (Table 1). SSRs from the palms and soles were normal in
all cases.
Quantitative Sensory Testing
There were no significant changes in monofilament (p = 0.17),
vibration (p= 0.45), or thermal thresholds (cool: p= 0.21; warm:
p = 0.18, cold pain: p = 0.13; heat pain: p = 0.32). There were
no baseline QST predictors of higher pain relief response (or
baseline predictors of skin biopsy nerve markers).
Immunohistochemistry
PGP9.5 IENFs and SENFs
Calf skin biopsies showed a significant increase in the density of
PGP9.5-positive intra-epidermal fibres (IENFs) (∗∗∗p < 0.0001,
Table 2, Figures 2A, 3). PGP9.5 IENFs were significantly lower
before but not after Capsaicin 8% patch application when
compared to healthy controls.
PGP9.5 sub-epidermal fibres (SENFs) were increased
significantly after Capsaicin 8% patch application (∗∗∗p <
0.0001, Table 2, Figures 2B, 3). PGP9.5 SENFs were significantly
lower before but not after Capsaicin 8% patch application, when
compared to healthy controls.
GAP43 SENFs
These was a significant increase in sub-epidermal nerve fibres
positive for GAP43 after treatment (∗∗∗p = 0.0001; Table 2,
Figures 4A–C). GAP43 SENFs showed no significant difference
from controls before Capsaicin 8% patch application but were
significantly increased after Capsaicin 8% patch application (∗∗∗p
< 0.0001; Figure 4C).
vWF
No changes in von Willebrand Factor (vWF) were observed
after treatment (Table 2, note n = 15 sample pairs, one sample
could not be analysed for this marker for technical reasons).
Comparison with controls showed significantly higher levels of
vWF both before and after treatment (∗∗p < 0.0001 and ∗∗p =
0.007, respectively), as we have reported previously in a different
cohort of subjects with NFCI (3).
Correlations
The increase of IENFs correlated significantly with reduction of
spontaneous (Spearman r: −0.55; p = 0.027) and cold-evoked
pain (Spearman r:−0.57; p= 0.019; Figure 5).
DISCUSSION
NFCI affects civilians exposed to cold environments relating
to certain occupations and leisure activities, but especially to
military service personnel during training or active duty. While
the improvement of preventive measures has helped reduce the
incidence of NFCI, there is a major current unmet need for the
effective treatment of chronic neuropathic pain in NFCI, and the
underlying pathological changes.
In this initial study, the Capsaicin 8% patch (Qutenza)
as licenced was well-tolerated and effective for reducing
neuropathic pain, for up to 3 months after a single 30-minute
application. Participants with chronic NFCI symptoms showed
significant decrease in both spontaneous pain and cold-evoked
pain, and the time-course of pain relief over 3 months following
Capsaicin 8% treatment was virtually identical to other painful
neuropathies e.g., painful diabetic neuropathy and chemotherapy
induced painful neuropathy (10–13). Importantly, the Patient
Global Impression of Change showed significant improvement.
NIS-LL score was unchanged, which was not unexpected, as it
includes motor function, which is not usually affected in NFCI.
Quantitative sensory tests showed no change, as previously (10,
13); it may be early to see functional changes with QST just 3
months after treatment.
The symptoms of NFCI are generally treated with current
oral medications used for chronic pain, including neuropathic
pain, though some studies have assessed the efficacy of new
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FIGURE 3 | Skin sections staining for PGP9.5 before and after application of Capsaicin 8% patch. (A) Control skin biopsy section, from a healthy human volunteer
(intra-epidermal nerve fibre marked with arrowhead, and sub-epidermal nerve fibre with arrow). (B) Skin biopsy section from a participant with NFCI, pre-treatment
(Q PRE); few intra-epidermal nerve fibres and sub-epidermal nerve fibres were observed before Capsaicin 8% patch Qutenza (Q) application. (C) Skin biopsy section
from same participant as above with NFCI, post-treatment (Q POST); 3 months after Capsaicin 8% patch application, the abundance of both the IENFs and SENFs
appeared restored. Magnification ×40.
treatments (23). A range of nerve fibre, vascular and ion channel
mechanisms have been reported by us to underlie chronic NFCI
(3), which represent potential new targets for pain relief. A key
finding is loss of intra-epidermal nerve fibres, which comprise
small sensory fibres, including nociceptors. This reduction in
intra-epidermal nerve fibre density in the skin, with dysfunction
of the residual small sensory nerve fibres e.g., hyperactivity, is
present in many other causes of painful neuropathy (3, 10, 13).
The mechanisms of neuropathic pain in these neuropathies,
and the effect of Capsaicin 8% patch, has been reviewed in detail
previously (3, 10, 19). It has also been shown by us, in another
chronic neuropathic condition (chemotherapy-induced painful
neuropathy, CIPN), to produce pain relief and regeneration and
restoration of sensory nerve fibres i.e. ameliorate the pathological
changes (13). Our hypothesis was that a single application of
capsaicin 8% patch may relieve pain and also induce nerve
regeneration or restoration of the nerve fibre phenotype, by
“pruning” the abnormal small sensory fibres (nociceptors), which
selectively express TRPV1, the heat and capsaicin receptor.
As the patients were now not receiving chemotherapy (and
here not re-exposed to Non-freezing cold injury conditions
recently), which may adversely affect both nerves and their
target skin cells (3, 10, 13), hence nerve fibres may regenerate
more “normally”. In accord with our hypothesis, this study
showed a significant increase of small sensory nerve fibres
(IENFs) with PGP9.5, and also of regenerating nerve fibres
with their selective marker GAP43. Further, the increase of
IENFs correlated significantly with reduction of spontaneous and
cold-evoked pain.
Randomised placebo-controlled clinical trials are clearly
required in NFCI, based on our initial findings. Previous
studies with the Capsaicin 8% patch in patients with painful
diabetic neuropathy provide useful insights into mechanisms
and support future clinical trials. In one study, the effects of
a single Capsaicin 8% patch application identified subgroups
i.e. 32% showed reduction in pain that was maximum in week
3, followed by a slow return towards baseline, 34% showed
reduction in pain that persisted at week 12 i.e. no return to
baseline pain, and 31% showed no change in pain scores (24).
A repeat treatment safety study, with 2-monthly Capsaicin 8%
patch over a 12 month period, showed progressive improvement
of pain scores in patients with diabetic peripheral neuropathy,
compared to standard of care treatment alone (25). These studies
support a randomised clinical trial with repeated 3-monthly
application of the Capsaicin 8% patch in NFCI subjects over
one year, with use of low dose (0.075%) patch as placebo, to
study the reversal of pain symptoms and pathological changes
in NFCI.
Further studies may elucidate the mechanisms and functional
effects of the Capsaicin 8% patch, particularly the time-course
in relation to pathophysiological changes that underlie chronic
NFCI (3). It is proposed that the milieu for regeneration and
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FIGURE 4 | Immunohistochemistry results in skin biopsies for GAP3 nerve fibres. (A) NFCI skin biopsy section before treatment with Capsaicin 8% patch (Q PRE):
sub-epidermal nerve fibres (arrows) were present, at a density similar to control/normal skin. (B) NFCI skin biopsy section in the same participant as above,
post-treatment (Q POST); skin biopsy collected 3 months after Capsaicin 8% patch Qutenza (Q) application: note the marked increase of GAP 43 positive SENFs in
length and thickness. Original magnification ×20. (C) Sub-epidermal GAP43 nerve fibres (SENFs; % Area) at pre-treatment visit (Q PRE) and visit 3 months after
treatment (Q POST) with Capsaicin 8% patch Qutenza (Q). Statistically significant increase of SENFs at 3 months after Capsaicin 8% patch application (paired t-test).
Statistically non-significant difference between control group and treated group before treatment (Q PRE), but statistically significant difference between control group
and treated group after Capsaicin 8% patch application (Q POST) (Mann-Whitney test).
FIGURE 5 | Correlations between changes in intra-epidermal nerve fibre density and pain relief. Decrease in pain scores in spontaneous pain (A) and cold evoked
pain (B) were correlated with changes in density of PGP 9.5 nerve fibres 3 months after the application of Capsaicin 8% patch, Spearman test; p values were
respectively p = 0.027 and p = 0.019.
phenotypic maturation would bemore favourable for the residual
small sensory nerve fibres “pruned” by capsaicin in this NFCI
study, as previously in CIPN (13). However, this favourable
milieu requires molecular characterisation, including changes
in expression of cutaneous neurotrophic factors, and their
interactions with regenerating nerve fibres. These interactions
may lead to normalisation of stimulus transduction at nerve
terminals e.g., mediated by TRP receptors, and the onward
propagation of impulses e.g., via sodium channels. Sensory
receptor and ion channel changes for sensory nerve functionmay
thus take longer than structural nerve improvements i.e. longer
than 3 months. Similar regenerative effects may occur following
terminal axotomy of nerve fibres not expressing TRPV1, by
agents other than capsaicin.
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There is no simple correlation between intra-epidermal nerve
fibre density and neuropathic pain, or sensory thresholds. Early
serial sensory testing after Capsaicin 8% patch treatment e.g.,
when most effective for pain relief in NFCI, and at later stages
after repeat applications, are thus of interest. Capsaicin has
significant effects only on TRPV1 expressing cells, the small
sensory nerve fibres, and not on blood vessels, hence the latter
did not show changes in this study; the vasculature may change
over time following interactions with regenerated nerve fibres,
and lack of exposure to cold conditions.
In conclusion, this study provides evidence for treatment of
NFCI with the Capsaicin 8% patchQutenza, for both neuropathic
relief, and regeneration and restoration of nerve fibres. However,
randomised clinical trials are required, to establish its effects
on pain relief and “disease-modification” i.e. reversal of the
underlying pathophysiological effects.
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